Clinical trials: Diabetic Nephropathy.
Diabetic Nephropathy
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety…
- Trial name
- NCT00044148
- Testing
- LY333531
- Where
- 15 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chromaderm, Inc.
Mild Nephropathy, Moderate Nephropathy
Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function
24 diabetics with mild \& moderate renal disease and 12 diabetics without renal disease. One screening, one dosing \& one follow-up visit with Technosphere® Inhalation Powder given at Visit 2 via MedTone® Inhaler and PK testing…
- Conditions
- Mild Nephropathy, Moderate Nephropathy, Diabetes Mellitus
- Trial name
- NCT00626249
- Testing
- Technosphere Inhalation Powder
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mannkind Corporation
Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease
Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal…
- Conditions
- Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease
- Trial name
- QRX-3 in CKD (NCT06948292)
- Testing
- QRX-3
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Ebima Clifford Okundaye
Renal Disorder
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
- Trial name
- NCT00140985
- Testing
- MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks
- Volunteers
- 97 people
- Sponsor
- Organon and Co
Diabetic Kidney Disease, Proteinuria
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
This study aims to observe changes in various indicators of renal function, such as proteinuria at different time points: short-term (Week 8), 6 months (Week 26), and a year (Week 52), in patients with DKD and hypertension, who…
- Conditions
- Diabetic Kidney Disease, Proteinuria, Hypertension,Essential
- Trial name
- FINALE (NCT05086549)
- Where
- South Korea
- Volunteers
- 360 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetic Kidney Disease, Chronic Kidney Disease Stage 1
Prospective Decision Impact Trial of KidneyIntelX
The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
- Trial name
- NCT04960514
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Kidney Disease
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy.
- Trial name
- BREAKOUT (NCT05709444)
- Testing
- Bremelanotide, RAAS inhibition therapy
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- Palatin Technologies, Inc
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
This study is being conducted to evaluate the safety and efficacy of treatment with CTP-499 for 24 weeks in patients with chronic kidney disease, Type 2 diabetic nephropathy and who are currently receiving treatment with an…
- Trial name
- NCT01487109
- Testing
- CTP-499
- Where
- 49 sites in United States
- Volunteers
- 170 people
- Sponsor
- Concert Pharmaceuticals
Diabetic Kidney Disease
Decision Impact Trial of KidneyIntelX
The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
- Trial name
- NCT04791358
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Renalytix AI, Inc.
Chronic Kidney Disease, Hypertension
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
This study determined the optimal starting dose of patiromer in treating hyperkalemia in participants with hypertension and diabetic nephropathy who were already receiving ACEI and/or ARB drugs, with or without spironolactone.
- Conditions
- Chronic Kidney Disease, Hypertension, Hyperkalemia
- Trial name
- AMETHYST-DN (NCT01371747)
- Testing
- patiromer, losartan, spironolactone
- Where
- 43 sites in Croatia, Georgia and 3 more
- Volunteers
- 324 people
- Sponsor
- Relypsa, Inc.